Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MZE782

Other · developed by Maze Therapeutics

Phase 2 Most advanced trial
MAZE Developer
1 Registered trials

What is MZE782?

MZE782 is an investigational drug studied in Phenylketonuria (PKU).

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Maze Therapeutics (MAZE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07694440 Phase 2 Phenylketonuria (PKU) Recruiting MAZE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Phenylketonuria (PKU)

More from Maze Therapeutics

Follow MAZE, the company behind MZE782

See MAZE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MAZE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.